511 related articles for article (PubMed ID: 35642667)
21. The CC ligand chemokine family members CCL17/CCL22 predict the survival and response to immune checkpoint blockade therapy of patients with head and neck squamous cell carcinoma.
Zhou W; Zhang X; Feng Y; Zhang Y; Liu Z
Curr Probl Cancer; 2022 Dec; 46(6):100896. PubMed ID: 36167005
[TBL] [Abstract][Full Text] [Related]
22. Head and neck cancer treatment in the era of molecular medicine.
Pandruvada S; Kessler R; Thai A
Adv Cancer Res; 2023; 160():205-252. PubMed ID: 37704289
[TBL] [Abstract][Full Text] [Related]
23. Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.
Valero C; Golkaram M; Vos JL; Xu B; Fitzgerald C; Lee M; Kaplan S; Han CY; Pei X; Sarkar R; Boe LA; Pandey A; Koh ES; Zuur CL; Solit DB; Pawlowski T; Liu L; Ho AL; Chowell D; Riaz N; Chan TA; Morris LG
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561583
[TBL] [Abstract][Full Text] [Related]
24. CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma.
Hoffmann F; Franzen A; de Vos L; Wuest L; Kulcsár Z; Fietz S; Maas AP; Hollick S; Diop MY; Gabrielpillai J; Vogt T; Kuster P; Zarbl R; Dietrich J; Kristiansen G; Brossart P; Landsberg J; Strieth S; Dietrich D
Clin Epigenetics; 2023 Jul; 15(1):112. PubMed ID: 37415208
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.
Oualla K; Castelo Branco L; Nouiyakh L; Amaadour L; Benbrahim Z; Arifi S; Mellas N
Cancer Control; 2021; 28():10732748211004878. PubMed ID: 33827280
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in head and neck squamous cell carcinoma: An updated review.
Parmar K; Mohamed A; Vaish E; Thawani R; Cetnar J; Thein KZ
Cancer Treat Res Commun; 2022; 33():100649. PubMed ID: 36279709
[TBL] [Abstract][Full Text] [Related]
28. Precision Medicine Gains Momentum: Novel 3D Models and Stem Cell-Based Approaches in Head and Neck Cancer.
Affolter A; Lammert A; Kern J; Scherl C; Rotter N
Front Cell Dev Biol; 2021; 9():666515. PubMed ID: 34307351
[TBL] [Abstract][Full Text] [Related]
29. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
[TBL] [Abstract][Full Text] [Related]
30. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
31. [Immunotherapy in head and neck squamous cell carcinoma : Abscopal effects in combination with radiotherapy, extraordinary responses in combination with chemotherapy, and pseudoprogression].
Brix N; Dunn L; Seiwert T; Belka C; Lauber K
Internist (Berl); 2020 Jul; 61(7):682-689. PubMed ID: 32462252
[TBL] [Abstract][Full Text] [Related]
32. Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma.
Secrier M; McGrath L; Ng F; Gulati S; Raymond A; Nuttall BRB; Berthe J; Jones EV; Sidders BS; Galon J; Barrett JC; Angell HK
Cancer Res Commun; 2023 Oct; 3(10):2133-2145. PubMed ID: 37819239
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
34. Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice.
Wang HC; Yeh TJ; Chan LP; Hsu CM; Cho SF
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076306
[TBL] [Abstract][Full Text] [Related]
35. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of carbonic anhydrases IX/XII by SLC-0111 boosts cisplatin effects in hampering head and neck squamous carcinoma cell growth and invasion.
Sarnella A; Ferrara Y; Auletta L; Albanese S; Cerchia L; Alterio V; De Simone G; Supuran CT; Zannetti A
J Exp Clin Cancer Res; 2022 Apr; 41(1):122. PubMed ID: 35365193
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers for immunotherapy response in head and neck cancer.
Gavrielatou N; Doumas S; Economopoulou P; Foukas PG; Psyrri A
Cancer Treat Rev; 2020 Mar; 84():101977. PubMed ID: 32018128
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
39. Tumor immune microenvironment in head and neck cancers.
Chen SMY; Krinsky AL; Woolaver RA; Wang X; Chen Z; Wang JH
Mol Carcinog; 2020 Jul; 59(7):766-774. PubMed ID: 32017286
[TBL] [Abstract][Full Text] [Related]
40. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
